Remove Diabetes Remove Drug Development Remove Immunity
article thumbnail

BioMed X and Sanofi partner to leverage AI for drug development

Pharmaceutical Technology

BioMed X has entered a research partnership with Sanofi to leverage artificial intelligence (AI) for drug development. This team will focus on creating a versatile computational platform that can precisely forecast the first-in-class drug candidates’ efficacy in virtual patient groups.

article thumbnail

Developing a first-in-class small molecule drug for inflammatory disease

European Pharmaceutical Review

Following her presentation on age-related disease at BioFuture 2023, Executive Vice President of Drug Development for MyMD Pharmaceuticals ® , Jenna Brager, shares with EPR why the company’s next-generation tumour necrosis factor (TNF)-alpha inhibitor has potential in inflammatory and autoimmune disorders.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

ZNA-1041 by F. Hoffmann-La Roche for Solid Tumor: Likelihood of Approval

Pharmaceutical Technology

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

article thumbnail

Two new drugs added to WHO list of COVID-19 therapies

pharmaphorum

The drug, developed by Incyte and licenced to Lilly, is also used to treat rheumatoid arthritis. It prevents the overstimulation of the immune system and is said to improve survival and reduce the need for ventilation in covid-19 patients, with no observed increase in adverse effects.

Hospitals 115
article thumbnail

Advancing microbiome innovation

European Pharmaceutical Review

While this approach has shown to be safe and efficient in Clostridium difficile, the variability between donors may lead to random outcomes and responses in patients for immune-mediated diseases. Notably, from one donor to another, significant variations exist. Internet] Pharmaceutical Technology.

article thumbnail

MP-0310 by Molecular Partners for Cervical Cancer: Likelihood of Approval

Pharmaceutical Technology

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

article thumbnail

MP-0310 by Molecular Partners for Colorectal Cancer: Likelihood of Approval

Pharmaceutical Technology

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.